Artera vs Indica Labs HALO AI

Indica's HALO AI is a research add-on inside HALO and HALO Link. A lab tunes its segmentation and classification tools by example, and the vendor says its software is deployed at all top 20 pharma companies. The clinical products carry other names, HALO AP Dx for primary diagnosis and HALO Prostate AI, which is CE-IVD marked. The add-on suits a research lab or pharma services group building its own classifiers.

Artera delivers a result from its own CLIA lab. A breast or prostate oncology team requests a risk score for early-stage HR+/HER2-negative invasive breast cancer or for prostate cancer, the analysis uses existing H&E slides with no extra staining, and ArteraAI Breast was cleared under K254115 on May 4, 2026. A 2025 Lancet Digit Health paper externally validated the multimodal prostate model in advanced disease, and many authors across Artera's papers are Artera-affiliated.

A lab training classifiers on its own slides looks to Indica, and a clinic that wants a prognosis score looks to Artera.